OIPE JUL 2 6 2001 E

0590

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Robert Martin Townsend, et al.

Serial No.: 09/896,784

Group Art Unit: Not Yet Assigned

Filing Date: June 29, 2001

**Examiner: Not Yet Assigned** 

For: PEPTIDE MIMICS OF THE CYTOKINE RECEPTOR COMMON GAMMA

CHAIN AND METHODS AND COMPOSITIONS FOR MAKING AND

**USING THE SAME** 

Date of deposit: July 24 2001

I Hereby certify that this paper is being deposited with the United States Postal Service as First Class Mail, postage prepaid on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

Commissioner for Patents, Washington, DC 2

Typed Name: Ellen M. Klann Registration No.: 44,836

Assistant Commissioner for Patents Washington DC 20231

Dear Sir:

## INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

 $\boxtimes$ 

	In accordance with §1.129(a), this Information Disclosure Statement is being					
	filed in connection with $\square$ the first or $\square$ second After Final Submission,					
	therefore:					
	☐ Certification in Accordance with §1.97(e) is attached; or					
	The fee of $$240.00$ as set forth in $$1.17(p)$ is attached.					
	In accordance with §1.97(c), this Information Disclosure Statement is being filed					
	after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:					
٠	☐ Certification in Accordance with §1.97(e) is attached; or					
	The fee of $$240.00$ as set forth in $$1.17(p)$ is attached.					
	In accordance with §1.97(d), this Information Disclosure Statement is being filed					
	after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of §130.00 as set forth in §1.17(i)(1).					
	Copies of each of the references listed on the attached Form PTO-1449 are					
	enclosed herewith.					
	Copies of references listed on the attached Form PTO-1449 are enclosed herewith					
	EXCEPT THAT:					
	☐ In view of the voluminous nature of reference [list as appropriate], and					
	the likelihood that this reference is available to the Examiner, a copy is not enclosed herewith.					

- In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C.§120 have been made in the instant application:
- Copies of references AA-AL listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 09/020,065, filed February 6, 1998.
  - ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date: July 24, 2001

Ellen M. Klann

Registration No. 44,836

WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP One Liberty Place - 46th Floor Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 1997 WWKMN



Sheet 1 of 2

W TH:TOE			Sheet 1 01 2			
Form 1	PTO-1449 Modified	Docket No. TJU-2498	Serial No. 09/896,784			
C	Patent and Publications Cited by Applicant veral sheets if necessary)	Applicant Robert Martin Townsend, et al.				
	epartment of Commerce and Trademark Office	Filing Date Group June 29, 2001 Not Yet Assigned				
ОТНЕ	R DOCUMENTS (Including Autho	r, Title, Date, Pertine	ent Pages, Etc.)			
· AA	Boussiotis et al., "Prevention of T C the IL-2 Receptor", Science, 1994, 2		ng Through the γ <sub>c</sub> Chain of			
AB	<ul> <li>AB deVos et al., "Human Growth Hormone and Extracellular Domain of Its Receptor: Crystal Structure of the Complex", Science, 1992, 255, 306-312</li> <li>AC Finn, F.M. et al., in The Proteins, Vol. II, 3d Ed., Neurath, H. et al. (eds.), Academic Press, New York, NY, 1976, 105-253</li> <li>AD Gustchina, et al., "A Model of the Complex Between Interleukin-4 and Its Receptors", Proteins: Structure, Function and Genetics, 1995, 21, 140-148</li> <li>AE Kent et al., "Modern Methods for the Chemical Synthesis of Biologically Active Peptides", in Synthetic Peptides in Biology and Medicine, Alitalo, K. et al. (eds.), Elsevier Science Publishers, Amsterdam, 1985, 29-57</li> <li>AF Merrifield, "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide", J. Am. Chem. Soc., 1963, 15, 2149-2154</li> <li>AG Miyazaki, T. et al., "Functional Activation of Jak1 and Jak3 by Selective Association with IL-2 Receptor Subunits", Science, 1994, 266, 1045-1047</li> <li>AH Noguchi, M. et al., "Interleukin-2 Receptor γ Chain Mutation Results in X-Linked Severe Combined Immunodeficiency in Humans", Cell, 1993, 73, 147-157</li> </ul>					
AC						
AD						
AE						
AF						
AG						
АН						
AI	Russell, S.M. et al., "Interaction of IL-2Rβ and γ <sub>c</sub> Chains with Jak1 and Jak3: Implications for XSCID and XCID", <i>Science</i> , <b>1994</b> , <i>266</i> , 1042-1044					
AJ	Townsend, R.M. et al., "Peptide Mimi J. Allergy Clin. Immunol., 1997, 99	-				
EXAMINER		DATE CONSIDER	RED			

PRADEMARK	<u> </u>					Sheet 2 of 2
Form PTO-1449 Modified				Docket No. TJU-2498	Serial No. <b>09/896,784</b>	
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Applicant Robert Martin Townsend, et al.		
				Filing Date June 29, 2001	Group Not Yet Assigned	
		U.	S. PATENT D	OCUMENTS		
Examiner Initial		Document No.	Date	Name	Class	Subclass
	<u> </u>					
				,		
	T	FORI	EIGN PATENT	T DOCUMENTS	1	
Examiner Initial		Document No.	Date	Country	Translation YES NO	
	AK	WO 95/11312	04/27/95	PCT	X	
-	AL	WO 97/28190	08/07/97	PCT	х	
				DATE CONST	EDED	
EXAMINER				DATE CONSIDERED		